<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical data and hematological features of 29 children, under the age of 12 years, with primary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> are presented </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis was made using the FAB (French-American-British) Cooperative Group criteria </plain></SENT>
<SENT sid="2" pm="."><plain>There were 24 males and 5 females aged 4 months to 12 years (median 2.5 years) with marked male preponderance </plain></SENT>
<SENT sid="3" pm="."><plain>Childhood <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> constituted 16% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> and 36.7% of <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The median duration of symptoms prior to diagnosis was 3 months </plain></SENT>
<SENT sid="5" pm="."><plain>There were 15 cases of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>, one of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, 3 of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation and 10 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients evolved to <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid and 4 to <z:hpo ids='HP_0006721'>acute lymphatic leukemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The median duration of preleukemic phase in these patients was 7 months (range 4-29 months) </plain></SENT>
<SENT sid="8" pm="."><plain>The overall mean survival was short (5-9 months) in <z:hpo ids='HP_0000001'>all</z:hpo> the subgroups </plain></SENT>
<SENT sid="9" pm="."><plain>Besides supportive therapy in most patients, two patients were treated with <z:chebi fb="0" ids="4911">etoposide</z:chebi>, one with alfa interferon 2b and one with high dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Our results show that <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> is not infrequent in children </plain></SENT>
<SENT sid="11" pm="."><plain>The disease has an aggressive clinical course and may evolve into <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>